Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade
Open Access
- 1 January 2017
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 9 (2) , 74-79
Abstract
Over the last decade, the role of renin-angiotensin system (RAS) on the development of obesity and its comorbidities has been extensively addressed. Both circulating and local RAS components are up-regulated in obesity and involved in non-alcoholic fatty liver disease onset. Pharmacological manipulations of RAS are viable strategies to tackle metabolic impairments caused by the excessive body fat mass. Renin inhibitors rescue insulin resistance, but do not have marked effects on hepatic steatosis. However, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARB) yield beneficial hepatic remodeling. ARBs elicit body mass loss and normalize insulin levels, tackling insulin resistance. Also, this drug class increases adiponectin levels, besides countering interleukin-6, tumoral necrosis factor-alpha, and transforming growth factor-beta 1. The latter is essential to prevent from liver fibrosis. When conjugated with peroxisome proliferator-activated receptor (PPAR)-alpha activation, ARB fully rescues fatty liver. These effects might be orchestrated by an indirect up-regulation of MAS receptor due to angiotensin II receptor type 1 (AT1R) blockade. These associations of ARB with PPAR activation and ACE2-angiotensin (ANG) (1-7)-MAS receptor axis deserve a better understanding. This editorial provides a brief overview of the current knowledge regarding AT1R blockade effects on sensitivity to insulin and hepatic structural alterations as well as the intersections of AT1R blockade with peroxisome proliferator-activated receptor activation and ACE2-ANG (1-7) - MAS receptor axis.Keywords
This publication has 54 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptors-Alpha and Gamma Are Targets to Treat Offspring from Maternal Diet-Induced Obesity in MicePLOS ONE, 2013
- The renin‐angiotensin system: a link between obesity, inflammation and insulin resistanceObesity Reviews, 2011
- Review article: pancreatic renin-angiotensin systems in health and diseaseAlimentary Pharmacology & Therapeutics, 2011
- A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat DietJournal of Clinical Biochemistry and Nutrition, 2010
- The sweeter side of ACE2: Physiological evidence for a role in diabetesMolecular and Cellular Endocrinology, 2009
- Obesity and Nonalcoholic Fatty Liver DiseaseNutrition Reviews, 2008
- Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injuryCritical Care Medicine, 2008
- Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2008
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998